Antiverse

Antiverse, a biotech firm headquartered in Wales, has successfully completed a Series A funding round, securing £7 million to advance its AI-driven therapeutic antibody technology.

Summary of transaction details:

• Value: £7,000,000
• Sector: Biotechnology / AI Drug Discovery
• Advisor: Not specified
• Key Entities: Target: Antiverse; Lead Investor: Soulmates Ventures; Additional Investors: Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital, i&i Biotech Fund
• Location: Cardiff, UK

Note: This significant capital injection will enable Antiverse to scale its generative antibody design platform, deepen strategic partnerships, and accelerate its mission to develop therapies for previously 'undruggable' molecular targets, solidifying its position in the drug discovery landscape.